Edesa Biotech (EDSA) EBITDA (2013 - 2026)
Edesa Biotech (EDSA) posted EBITDA of -$2.3 million for Q4 2025, up 5.22% sequentially from -$2.5 million in Q3 2025, and down 23.32% YoY from -$3.1 million in Q4 2024.
Edesa Biotech (EDSA) EBITDA (2013 - 2026) Analysis & Trends
Edesa Biotech has reported EBITDA for 13 years, with the latest figure at -$2.3 million in Q4 2025.
- Quarterly EBITDA fell 23.32% year-over-year to -$2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.4 million (down 18.4% YoY) and the FY2025 annual result came in at -$7.9 million, down 12.78% from the prior year.
- EBITDA improved to -$2.3 million in Q4 2025 per EDSA's latest filing, from -$2.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$1.0 million in Q3 2024 and troughed at -$9.5 million in Q1 2021.
- A 5-year average of -$3.3 million and a median of -$2.4 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2021 and 2023: EBITDA slumped 527.23% in 2021, then soared 64.39% in 2023.
- Over 5 years, EBITDA stood at -$5.2 million in 2021, then jumped by 53.92% to -$2.4 million in 2022, then advanced by 21.9% to -$1.9 million in 2023, then fell by 2.22% to -$1.9 million in 2024, then fell by 23.32% to -$2.3 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$2.3 million, -$2.5 million, and -$1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - | -5.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.52 Mn |
| Dec 31, 2025 | -2.34 Mn |
| Sep 30, 2025 | -2.47 Mn |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -2.22 Mn |
| Dec 31, 2023 | -1.86 Mn |
| Sep 30, 2023 | -2.37 Mn |
| Jun 30, 2023 | -2.06 Mn |
| Mar 31, 2023 | -2.41 Mn |
| Dec 31, 2022 | -2.38 Mn |
| Sep 30, 2022 | -2.84 Mn |
| Jun 30, 2022 | -5.80 Mn |
| Mar 31, 2022 | -4.58 Mn |
| Dec 31, 2021 | -5.16 Mn |
| Sep 30, 2021 | -5.48 Mn |
| Jun 30, 2021 | -6.07 Mn |